Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on April 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from 9 to 10 directors with Habib J. Dable appointed as Class II director through the 2026 annual meeting.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 9 to 10 directors with Habib J. Dable appointed as Class II director through the 2026 annual meeting
- Dable brings former Acceleron CEO experience and current board roles across Spyglass Pharma, Relay Therapeutics, Day One, and PepGen
- Initial equity award: options for 44,400 shares, vesting monthly over 36 months at grant-date fair market value
- Nasdaq independence determination supports governance compliance and adds experienced biopharmaceutical leadership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.